# A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT06022861** · PHASE3 · RECRUITING · sponsor: **Shandong Boan Biotechnology Co., Ltd** · enrollment: 510 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** LY01015
- **DRUG:** Fluorouracil
- **DRUG:** Cisplatin
- **DRUG:** Opdivo®

## Key facts

- **NCT ID:** NCT06022861
- **Lead sponsor:** Shandong Boan Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-12
- **Primary completion:** 2025-06
- **Final completion:** 2026-12
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022861, "A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06022861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*